Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of “Buy” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given an average recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $25.60.

A number of equities research analysts recently commented on ATXS shares. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Monday, January 13th.

Astria Therapeutics Stock Performance

NASDAQ ATXS opened at $7.50 on Monday. Astria Therapeutics has a 52-week low of $6.95 and a 52-week high of $16.90. The business has a 50 day simple moving average of $9.43 and a 200 day simple moving average of $10.62. The stock has a market cap of $423.23 million, a price-to-earnings ratio of -3.59 and a beta of 0.70.

Hedge Funds Weigh In On Astria Therapeutics

A number of large investors have recently modified their holdings of ATXS. SG Americas Securities LLC increased its position in shares of Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 7,218 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Astria Therapeutics by 101.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 19,735 shares during the last quarter. Barclays PLC raised its stake in shares of Astria Therapeutics by 70.5% during the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock worth $1,020,000 after purchasing an additional 38,321 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Astria Therapeutics by 8.7% in the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 11,763 shares during the last quarter. Finally, RA Capital Management L.P. grew its stake in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after buying an additional 61,457 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.